A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This open-label, single arm study evaluated the efficacy and safety of RoActemra/Actemra
(tocilizumab) in patients with rheumatoid arthritis. Patients received RoActemra/Actemra 8
mg/kg intravenously every 4 weeks, alone or in combination with standard anti-rheumatic
therapy, for 12 weeks.